Brexit and the Impact to Your Global Business Operations - Webinar Recording/Transcript
Brexit and the Impact to Your Global Business Operations: What Life Sciences Companies Need to Know Now
Your international drug and device business is at a crossroads known as Brexit — the withdrawal of the United Kingdom (UK) from the European Union (EU).
What can you expect?
The EMA is moving to from London to Amsterdam in March 2019 — and will lose a 30 percent of its staff. The agency has already stopped accepting and publishing clinical trials data.
What about the legal uncertainty regarding contracts involving both the UK and other EU member states?
Brexit is about to happen and you need to make plans before it does. Prepare to discover:
- The impact on international harmonization efforts — the EMA will “only take a reactive role,” focus on “urgent” drug safety guidelines and limit travel to “Brexit-related interactions.”
- How to deal with the legal uncertainty introduced into contracts involving both the UK and EU member states
- And much more…
Brexit will be finalized on March 29, 2019. You need to know how it will impact your global operations. Order today to minimize potential disruptions.